Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07759687
NCT07759687Not yet recruitingNot Applicable

Development of Optimal Acute Dosing of Lion's Mane Mushroom on Attention and Mood: A, Double-blind, Placebo- Controlled, Crossover Study

Northumbria University1 site in 1 country24 target enrollmentStarted: August 1, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
24
Locations
1
Primary Endpoint
Speed of Attention
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The primary purpose of the research is to evaluate in healthy adults the time course effects of varying dosages of Lion's mane mushroom on attention and mood.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Basic Science
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Participants must self-assess themselves as being in good health
  • •Participants must be aged 18 to 45 at the time of giving consent
  • •Understand and are willing to participate in all scheduled visits and to adhere to the trial procedures outlined in the subject information sheet
  • •Are fluent in English (equivalent to IELTS Level 6)

Exclusion Criteria

  • •Have any pre-existing medical condition/illness which will impact taking part in the study. There may be other, unforeseen, exceptions and these will be considered on a case-by-case basis, i.e., participants may be allowed to progress to screening if they have a condition/illness which would not interact with the active treatments or impede performance so it's worth discussing any medical conditions with the researcher prior to booking lab appointments. NOTE: the explicit exceptions to this is controlled hayfever, asthma, hypo/hyperthyroidism, high blood pressure, high cholesterol, reflux.
  • •Are currently taking prescription medications NOTE: the explicit exceptions to this are contraceptive treatments, and those taken 'as needed' in the treatment of asthma and hay fever. There may be other instances of medication use which, where no interaction with the active treatments is likely, and which would not be expected to have any impact on brain function, participants may be able to progress to screening.
  • •Have a history of experiencing difficulty swallowing tablets including in capsule form
  • •Have high blood pressure (systolic over 139 mm Hg or diastolic over 89 mm Hg)
  • •Have a Body Mass Index (BMI) outside of the range 18.5-35 kg/m2 (unless waist to hip ratio is less than or equal to 0.85 (female) or 0.90 (male))
  • •Engage in the extreme dietary habit of intermittent fasting, as judged by the Investigator
  • •Are pregnant, seeking to become pregnant or lactating
  • •Have been diagnosed with a neurological condition, or assessed as having a learning/behavioural or neurodevelopmental difference such as dyslexia, autism, or ADHD
  • •Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness)
  • •Use illegal/recreational drugs
  • •Have relevant food allergies/intolerances/ sensitivities
  • •Consume over 500mg of caffeine per day
  • •Have taken dietary supplements e.g., Vitamins, omega 3 fish oils etc. in the last 4 weeks (Note: participation is possible following a 4-week supplement washout prior to participating and for the duration of the study on the proviso that the supplements they are taken are out of choice and not medically prescribed or advised). NOTE - Vitamin D and iron supplements are allowed for this trial if they have been advised by GP to increase levels to a normal range and have been taken for at least 4 weeks consistently and will be taken consistently throughout the trial.
  • •Are currently participating in any other chronic clinical or nutrition intervention studies, or have done so in the past 4 weeks
  • •Have taken antibiotics within the past 4 weeks
  • •Has been diagnosed with/ undergoing treatment for alcohol or drug abuse in the last 12 months
  • •Have been diagnosed with/ undergoing treatment for a psychiatric disorder in the last 12 months (including medically diagnosed anxiety, depression or stress-related disorders).
  • •Have any health condition that would prevent fulfilment of the study requirements (this includes non-diagnosed conditions for which no medications may be taken)
  • •Suffers from frequent migraines that require medication (more than or equal to 1 per month)
  • •Not be a native speaker of English or at least fluent in English
  • •Smoke tobacco or vape nicotine or use nicotine replacement products
  • •Have worked night shift the night prior to attending the laboratory
  • •Are unable to demonstrate adequate minimal performance on lab, computer-based cognitive tasks
  • •Have any known active infections
  • •Do not have a bank account (required for payment)

Arms & Interventions

Placebo

Placebo Comparator

Placebo capsules (microcrystalline cellulose)

Intervention: Placebo (Dietary Supplement)

50mg Lion's Mane

Experimental

50 mg Lion's Mane fruiting body extract (20:1 ratio)

Intervention: Lion's Mane fruiting bodies extract (Dietary Supplement)

100mg Lion's Mane

Experimental

100 mg Lion's Mane fruiting body extract (20:1 ratio)

Intervention: Lion's Mane fruiting bodies extract (Dietary Supplement)

150mg Lion's Mane

Experimental

150 mg Lion's Mane fruiting body extract (20:1 ratio)

Intervention: Lion's Mane fruiting bodies extract (Dietary Supplement)

1.5g Lion's Mane

Experimental

1.5g Lion's Mane fruiting body extract (20:1 ratio)

Intervention: Lion's Mane fruiting bodies extract (Dietary Supplement)

Outcomes

Primary Outcomes

Speed of Attention

Time Frame: Baseline, 60-, 120-, 180- and 300 minutes post dose

Speed of Attention cognitive domain, calculated from reaction time (msec) performance on the following tasks: Choice Reaction Time, 4 Choice Reaction Time, Digit Vigilance, Arrow Flankers, Stroop, Rapid Visual Information Processing.

Secondary Outcomes

  • Accuracy of Attention(Baseline, 60-, 120-, 180- and 300 minutes post dose)
  • Choice Reaction Time(Baseline, 60-, 120-, 180- and 300 minutes post dose)
  • 4 Choice Reaction Time(Baseline, 60-, 120, 180-, and 300 minutes post dose)
  • Digit Vigilance(Baseline, 60-, 120, 180-, and 300 minutes post dose)
  • Arrow Flankers(Baseline, 60-, 120, 180-, and 300 minutes post dose)
  • Stroop(Baseline, 60-, 120, 180-, and 300 minutes post dose)
  • Numeric Working Memory(Baseline, 60-, 120, 180-, and 300 minutes post dose)
  • Serial Subtraction of three's(Baseline, 60-, 120, 180-, and 300 minutes post dose)
  • Serial Subtraction on Seven's(Baseline, 60-, 120, 180-, and 300 minutes post dose)
  • Rapid Visual Information Processing(Baseline, 60-, 120, 180-, and 300 minutes post dose)
  • Positive and Negative Affect Scale (PANAS)(Baseline, 60-, 120-, 180- and 300 minutes post dose)
  • Visual Analogue Mood Sales (VAMS)(Baseline, 60-, 120, 180-, and 300 minutes post dose)
  • Stress Visual Analogue Scales(Baseline, 60-, 120, 180-, and 300 minutes post dose)
  • Systolic Blood pressure(Baseline, 60-, 120-, 180-, and 300- minutes post dose.)
  • Diastolic Blood pressure(Baseline, 60-, 120-, 180-, 300- minutes post dose)
  • Heart Rate(Baseline, 60-, 120-, 180-, 300- minutes post dose)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ellen Smith

Principal Investigator

Northumbria University

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Effects of Two Different Lion's Mane Extracts (Lions Mane Fruiting Body & Lions Mane Fruiting Body With Mycellium) on Cognitive Performance, Subjective Affect, Serum Biomarkers, and Gut Microbiota in Healthy AdultsHealthy Adult FemalesHealthy Adult Male
NCT07405957Applied Food Sciences Inc.87
Not yet recruiting
Not Applicable
Comparison of effect of Mannitol and mannitol plus glycerol combination on brain relaxation and systemic hemodynamics in elective tumor surgeries- A Randomized Controlled TrialMalignant neoplasm of cerebrum, except lobes and ventricles,
CTRI/2025/05/087889Jipmer Intramural Fund70
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsAdvanced Breast CancerMetastatic Breast Cancer (HR+/ HER2-)Metastatic Colorectal AdenocarcinomaTriple Negative Breast CancerColorectal Cancer
NCT07318805Pfizer260
Not yet recruiting
Phase 2
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.Breast Cancer (Triple Negative Breast Cancer (TNBC))
NCT07487519Shanghai Henlius Biotech180
Recruiting
Phase 2
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCNon Small Cell Lung Cancer
NCT07269782Shanghai Henlius Biotech60